Towards Healthcare
Global Insulin Market Size Envisioned at USD 41.63 Billion by 2033

Global Insulin is Estimated to Hit USD 41.63 Billion Market Size by 2033

Status: Published Category: Therapeutic Area Insight Code: 5101 Format: PDF / PPT / Excel

Report Highlights:

  • The global insulin market size hit USD 28.33 billion in 2023.
  • It is projected to reach USD 41.63 billion market size by 2033.
  • It is set for a 4.2% annual climb till 2033.
  • Analogs, lab-made versions, dominated the field in 2023 with a commanding 69.3% share.
  • Asia Pacific took the biggest slice of the pie in 2023, gobbling up 42.6% of the insulin market.
  • Rapid-acting insulin delivering a quick sugar blast will see the next decade's fastest growth (5.5%).

Global Insulin Market Size 2023 - 2033

Unlock Infinite Advantages: Subscribe to Annual Membership

The global impact of diabetes is profound, affecting around 422 million individuals worldwide. The majority of those affected reside in low-income countries and middle-income countries, contributing to 1.5 million annual deaths. The prevalence of diabetes continues to rise, necessitating a growing demand for human insulin.

According to the World Health Organization, diabetes is a chronic disease that causes blindness, kidney failure, heart attacks, strokes and lower limb amputations. Diabetes prevalence is increasing globally, with over half a billion confirmed and over half a billion cases by 2021. Imagine your body as a busy city; glucose (sugar) is the fuel that keeps everything running smoothly. Insulin is like the traffic cop, directing the glucose to the cells needing energy. When someone has diabetes, it's like having traffic issues – either there's not enough insulin (the traffic cop is on break), or the insulin isn't doing its job correctly (the traffic cop is confused). Human insulin steps in as a superhero traffic cop. It's created in a lab but acts like our bodies naturally produce insulin. People with diabetes, instead of relying on their body's traffic cop, use injections of human insulin to get the glucose where it needs to go. So, it's like having a trustworthy substitute traffic cop to prevent traffic jams (high blood sugar) or empty roads (low blood sugar). This way, the city (your body) can function smoothly, and people with diabetes can do their daily activities without worrying about glucose chaos.

The research has primarily focused on the role of insulin in the onset and progression of pathological conditions and chronic diseases, such as diabetes.

According to the literature, insulin deficiency prevents cells from using glucose as energy. High glucose levels in the bloodstream cause hyperglycemia. Prolonged hyperglycemia causes diabetes mellitus and causes neurological damage as well as eye and kidney dysfunction. Similarly, a cell's inability to use glucose as an energy source due to a lack of insulin can cause it to rely solely on fat energy stores.

Effectively managing type 1 diabetes involves:

  • Imitating the actions of pancreatic beta cells
  • Recognizing when insulin is necessary
  • Administering it as needed

Insulin, a natural hormone, plays a vital role in addressing various conditions such as type 2 diabetes, gestational diabetes, and complications like diabetic ketoacidosis. Beyond that, insulin offers valuable support in critical illnesses to tackle hyperglycemia-related concerns proactively. Regarding elevated triglyceride levels, insulin steps in by boosting the formation of lipoprotein lipase, which aids in reducing triglyceride levels. This proves especially beneficial in cases of severe hypertriglyceridemia, where a rapid insulin infusion can swiftly bring down triglyceride concentrations, contributing to improved overall health outcomes.

Global Insulin Adoption

The increasing adoption of insulin analogs is driving advancements in the market. These analogs, designed to closely mimic normal human physiology, exhibit pharmacodynamics and pharmacokinetic profiles closer to regular insulin. Studies indicate faster onset and offset of insulin effects than regular human insulin.

Age-Adjusted Calculated Prevalence of Newly Diagnosed Diabetes By Metropolitan Residence in the U.S., 2019 - 2021

Efforts are underway to enhance the effectiveness of insulin analogs, exemplified by the launch of products like PHEIVO. Notably, long-acting insulin analogs such as Detemir and Glargine offer benefits such as reduced variability, prolonged action duration, predictability, positive effects on weight, and fewer instances of hypoglycemia, especially during the night. These advantages contribute to the widespread use of analog insulin products globally.

Diabetes on the Rise

As more people are diagnosed with diabetes worldwide, there's a growing demand for insulin products. This surge is primarily due to the increasing prevalence of diabetes, a chronic condition that affects how the body uses insulin. Now, insulin is crucial for managing blood sugar levels, and with more individuals grappling with diabetes, the need for insulin has skyrocketed. Human insulin, made to resemble the insulin our bodies naturally produce, plays a crucial role in helping people with diabetes regulate their blood sugar. This uptick in demand isn't just a random occurrence—it's a direct result of the widespread occurrence of diabetes. As healthcare professionals work to meet the insulin needs of a larger diabetic population, the global insulin market is experiencing significant growth to keep pace with the global health challenge posed by diabetes.

Additionally, Pharmaceutical companies are continually innovating to meet the diverse needs of diabetic patients. The market has seen the development of different formulations, including long-acting and rapid-acting insulin, to provide more customized and effective treatment options. The growing prevalence of diabetes also underscores the importance of raising awareness about the condition and promoting a healthy lifestyle. Government, healthcare organizations, and communities are working together to implement preventive measures and improve access to diabetes education and care.

Some Notable CDC Highlights

  • Approximately 38.4 million folks in the US, which is around 11.6% of the population, have diabetes. Out of these, about 29.7 million have been diagnosed, including 29.4 million adults. Surprisingly, there are 8.7 million undiagnosed cases, making up 22.8% of undiagnosed adults. Now, when it comes to prediabetes, a whopping 97.6 million individuals aged 18 and above are dealing with it, making up about 38% of the adult population. If we focus on the 65 and older crowd, 27.2 million of them or nearly 48.8%, are navigating the territory of prediabetes. Stay informed and take care.
  • In 2021, the Tenth edition of the IDF Diabetes Atlas predicts that the number of people with diabetes will increase in the coming years. Many individuals, more than 9 million worldwide, are dealing with type 1 diabetes, where daily insulin is crucial for managing blood sugar levels. Approximately 10% of all diabetes cases are type 1, leading to a growing demand for human insulin globally and contributing to the market's expansion in the foreseeable future.

Global Total Diagnosed Diabetes Cases in 20-79 Age Group(in Million), 2021

Affordability Constraints

The paragraph highlights how the cost of human insulin is a key factor holding back its market growth. Imagine insulin as a lifeline for people with diabetes, and as more people need it, there's a struggle to produce enough without making it too expensive. Balancing the increasing demand with the need to keep insulin affordable is like walking a tightrope. An article from Pharma Boardroom highlights that India faces a challenge in lacking a proper reimbursement system for drugs, medical devices, and biologics. Instead, a significant portion of these expenses is covered out-of-pocket by individuals. Additionally, the market's growth is hindered by a notable number of undiagnosed diabetes cases in underdeveloped countries. This points to improved healthcare infrastructure and awareness to foster overall market development.

Think of it like this: making insulin involves various expenses, from production to meeting regulations. As more folks need insulin, ensuring it's available to everyone becomes a puzzle. The challenge lies in figuring out how to produce sufficient insulin without letting the costs. It's not just about making the insulin; it's about ensuring everyone who needs it can get it without breaking the bank. That's the intricate dance of factors in ensuring human insulin stays accessible to those who rely on it.

Expansion in New and Improved Versions in Insulin Sources

The market for human insulin is getting a boost because of new and improved versions of both human insulin and its analogues. These developments are making it easier to manage diabetes. Human insulin is a crucial hormone that helps control blood sugar levels, and now, it's getting upgrades through analogs—these are like synthetic copies of the body's natural insulin.

Over the last five years, there's been a noticeable increase in the popularity of analog insulin. And now, with the recent introduction of generic insulin, the growth of the analog insulin market is expected to get an extra boost.

For Instance,

  • In January 2020, Novo Nordisk A/S rolled out generic versions of NovoLog and Novolog mix, offering them a whopping 50.0% discount compared to their branded counterparts. This move will make these insulin options more accessible and affordable for people who need them.

These improvements lead to better and more user-friendly options, making treatments more effective. Ongoing research and development efforts are not just meeting the needs of people with diabetes but also helping the global insulin market grow overall. This positive impact is felt in healthcare and the lives of those dealing with diabetes.

Geographical Landscape

The geographical landscape of the global insulin market is diverse, with significant trends and variations across regions. In developed countries, a mature and well-established market for human insulin is driven by a higher prevalence of diabetes and a greater awareness of advanced treatment options. North America and Europe, for example, boast substantial market shares due to their healthcare infrastructure and emphasis on innovation.

On the other hand, emerging economies in Asia-Pacific, Latin America, and Africa are witnessing a growing demand for human insulin. Factors like population growth, lifestyle changes, and increasing healthcare awareness contribute to this expansion. In these regions, improving economic conditions also plays a role, allowing more individuals to afford diabetes management.

Overall, economic, demographic, and healthcare factors influence the global insulin market, creating a dynamic landscape with varying opportunities and challenges worldwide.

Competitive Landscape

The competitive landscape of the global insulin market is dynamic and characterized by several key players striving for innovation and market share. These industry giants often engage in strategic collaborations, acquisitions, and product launches to strengthen their positions. Additionally, the market sees the emergence of newer entrants and biotech firms, contributing to increased competition and fostering innovation. Factors influencing competition include product efficacy, pricing strategies, regulatory compliance, and the ability to adapt to evolving technologies. As the demand for advanced diabetes management solutions grows, companies focus on developing novel formulations, delivery methods, and personalized treatment options. The competitive landscape is further shaped by regional variations, with companies adapting their strategies to meet the specific needs and regulatory requirements of different markets. Overall, the global insulin market reflects a competitive environment driven by a constant pursuit of excellence in research, development, and market expansion.

Recent Breakthroughs in the Field

  • In April 2022, Biocion secured a 3-year, USD 90 million contract from the Ministry of Health in Malaysia for supplying Insugen, its recombinant human insulin. This move bolstered Biocion's presence in emerging markets like Malaysia.
  • In February 2022, Biocon joined forces with Viatris Inc. to acquire Viatris' biosimilar business, enhancing Biocon's research and development capabilities.
  • In November 2021, Biocon partnered with the Research Society for the Study of Diabetes in India (RSSDI) to introduce a comprehensive care program for type 1 diabetic patients, contributing to maintaining a positive brand image in the market.

In the century following insulin's discovery, numerous innovations and advances have occurred.

Global Insulin Market Discovery

Market Players

  • Eli Lilly
  • Novo Nordisk
  • Sanofi
  • Boehringer Ingelheim
  • Biocon
  • Lupin Ltd.
  • Wockhardt Ltd.
  • Becton, Dickinson and Company
  • B. Braun SE

Market Segment

By Drug Type

  • Rapid-Acting
  • Short-Acting
  • Intermediate-Acting
  • Premixed Long-Acting

By Source

  • Human Insulin
  • Insulin Analog

By Application

  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes

By Delivery Device

  • Vials and Syringes
  • Insulin Pens
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

About The Author

Namrata Bukshet is not just a market researcher; she is a detective, a storyteller, and a champion for healthier lives. Her journey began with a Bachelor of Pharmacy degree and a thirst for knowledge that led her to pursue a Post Graduate Diploma in Pharmaceutical Management. Her curiosity for consumer behaviour and market trends burned bright. She delved deep into the world of lifestyle disorders, conducting extensive research that sheds light on the intricate dance between personal choices and societal pressures. This exploration culminated in a groundbreaking paper on E-Biz: Indias 1st G2B Online Portal, presented at an international conference, where her insights resonated with a global audience. But Namrata has impact extends far beyond a single paper. Her expertise has shaped the very landscape of market research and pharmaceuticals. Her keen eye for detail and unwavering commitment to understanding the why behind consumer behaviour have made her a sought-after professional in the industry. She is the decoder ring that unlocks the secrets hidden within data, the translator who turns complex trends into actionable insights. As she continues to unravel the mysteries of consumer behaviour, she paves the way for a future where healthcare is not just about treatment but about understanding the why and building a bridge to a healthier world, one insightful discovery at a time.

FAQ's

Human insulin is a peptide hormone that plays a crucial role in regulating blood sugar levels in the human body. The pancreas produces it and helps cells absorb glucose from the bloodstream, providing energy. In medical contexts, human insulin can refer to insulin derived from human sources or produced using genetic engineering techniques known as recombinant DNA technology. This synthetic insulin is used to treat diabetes to replace or supplement the insufficient natural insulin produced by the body.

Human insulin is available in various forms, including Regular Insulin (Short-Acting), Intermediate-Acting Insulin, Long-Acting Insulin and Premixed Insulin. The specific form and combination of insulin prescribed depend on an individuals diabetes management plan, lifestyle and medical needs.

The increasing prevalence of diabetes worldwide significantly influences the global insulin market, with a rising number of diagnosed individuals leading to an expanding demand for insulin products.

World Health Organization, Center for Disease Control and Prevention, MedlinePlus(.gov), Food and Drug Administration, HHS.gov., Diabetes Education Online.